Who are EscharEx (EX-03)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NexoBrid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/escharex-ex-03.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

EscharEx (EX-03) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EscharEx (EX-03) (EscharEx (EX-03)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzymatic debriding agent. Area: Wound Care / Burn Treatment.

phase 3 Enzymatic debriding agent Proteolytic enzymes (bromelain-derived) Wound Care / Burn Treatment Small molecule Live · refreshed every 30 min

Target snapshot

EscharEx (EX-03) (EscharEx (EX-03)) — MediWound Ltd. EscharEx is a topical enzymatic debriding agent that selectively removes necrotic tissue from burns and wounds.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
EscharEx (EX-03) TARGET	EscharEx (EX-03)	MediWound Ltd	phase 3	Enzymatic debriding agent	Proteolytic enzymes (bromelain-derived)
NexoBrid	NexoBrid	MediWound Ltd	marketed	Enzymatic debriding agent	Bromelain (serine protease)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzymatic debriding agent class)

MediWound Ltd · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EscharEx (EX-03) — Competitive Intelligence Brief. https://druglandscape.com/ci/escharex-ex-03. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing